LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.

Kelli-Ann MonacoScott DelachJing YuanYuji MishinaPaul FordjourEmma LabrotDaniel McKayRibo GuoStacy HigginsHui Qin WangJinsheng LiangKaren BuiJohn GreenPeter AspesiJessi AmbroseFelipa A MapaLesley GrinerMariela JaskelioffJohn FullerKenneth CrawfordGwynn PardeeStephania WidgerPeter S HammermanJeffrey A EngelmanDarrin D StuartVesselina G CookeGiordano Caponigro

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

LXH254 is a novel RAF inhibitor, which is able to inhibit dimerized BRAF and CRAF, as well as monomeric BRAF, while largely sparing ARAF.

Keyphrases

metastatic colorectal cancer
wild type
robot assisted
signaling pathway
oxidative stress
cell proliferation
anti inflammatory
replacement therapy
minimally invasive